 - IND for LB-001 in methylmalonic acidemia MMA cleared in August 2020 , with first patient in Phase 12 SUNRISE trial expected to be enrolled in early 2021 - Fast Track designation for LB-001 in MMA received in November 2020 - F irst follow-on offering post-IPO closed in October 2020 